Delving into the Latest Updates on Sequel Pharmaceuticals, Inc. with Synapse

概览

关联

1

项与 Sequel Pharmaceuticals, Inc. 相关的药物

JTV-519

靶点

Potassium channel x RYR2 x Sodium channels x calcium channel

作用机制

钾离子通道阻滞剂 [+3]

在研机构

AETAS Pharma Co., Ltd. [+2]

原研机构

Japan Tobacco (Hong Kong) Ltd.

在研适应症

心房颤动 [+3]

非在研适应症

特应性皮炎 [+3]

最高研发阶段临床2期

首次获批国家/地区-

首次获批日期-

5

项与 Sequel Pharmaceuticals, Inc. 相关的临床试验

EUCTR2010-023101-35-DK

/ Not yet recruiting临床2期

TUNDRA-AF: A mulTi-center, randomized, doUble-bliNded, placebo-controlled Dose-escalating study of the effects of K201 on the RestorAtion of sinus rhythm in subjects with symptomatic Atrial Fibrillation of recent onset - TUNDRA-AF

开始日期2011-02-11

申办/合作机构

Sequel Pharmaceuticals, Inc.

NCT01259622

/ Terminated临床2期

A mulTi-center, Randomized, doUble-bliNded, Placebo-controlled Dose-escalating Study of the Effects of K201 on the RestorAtion of Sinus Rhythm in Subjects With Symptomatic Atrial Fibrillation of Recent Onset

The purpose of this study is to evaluate the effects of a single intravenous infusion of K201 compared to placebo in a dose escalating manner on conversion to sinus rhythm, reduction of subject's symptom score, and safety.

开始日期2011-02-01

申办/合作机构

Sequel Pharmaceuticals, Inc.

EUCTR2009-017838-44-DK

/ Not yet recruitingN/A

A Pilot Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Centered Safety, Tolerability and Preliminary Efficacy Study of K201 Oral for the Prevention of Atrial Fibrillation (AF) Recurrence in Subjects Post-Conversion from AF - ARCTIC-AF

开始日期2010-04-09

申办/合作机构

Sequel Pharmaceuticals, Inc.

100 项与 Sequel Pharmaceuticals, Inc. 相关的临床结果

登录后查看更多信息

0 项与 Sequel Pharmaceuticals, Inc. 相关的专利（医药）

登录后查看更多信息

100 项与 Sequel Pharmaceuticals, Inc. 相关的药物交易

登录后查看更多信息

100 项与 Sequel Pharmaceuticals, Inc. 相关的转化医学

登录后查看更多信息